Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225127 · ClinicalTrials.gov registry record
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
A clinical trial of Bladder Cancer and Recurrent Bladder Cancer, sponsored by University of Washington.
- Recruiting
- Registry status
- 408
- Enrollment target
- 6
- Study locations
NCT07225127 is a study of Bladder Cancer and Recurrent Bladder Cancer that is actively recruiting participants, run by University of Washington. The registered enrollment target is 408 participants, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT07225127, a study of Bladder Cancer and Recurrent Bladder Cancer, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- 408 participants
- Enrollment target
- 6
- Study locations
Study Summary
Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer Study 2 (CISTO2) has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. The purpose of CISTO2 is to conduct a large prospective study that directly compares the impact of bladder sparing therapies versus bladder removal in recurrent high-grade NMIBC patients on financial toxicity, clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Conditions Studied
Study Locations (6)
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Iowa
- University of Iowa - Iowa City
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- The Ohio State University - Columbus
Tennessee
- Vanderbilt University Medical Center - Nashville
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07225127
The ClinicalTrials.gov registry entry for NCT07225127 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07225127 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, Iowa, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07225127 about?
NCT07225127 is a clinical study titled "Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2". Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians....
What is the current status of trial NCT07225127?
This trial is currently recruiting. The enrollment target is 408 participants. The study started on 2025-11-03. Estimated completion is 2028-12.
What conditions does trial NCT07225127 study?
This clinical trial studies the following conditions: Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC).
Who is sponsoring clinical trial NCT07225127?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07225127 being conducted?
This trial has 6 study locations across Florida, Iowa, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.